ライフサイエンスコーパス: alcohol withdrawal

1 o neuronal hyperexcitability observed during alcohol withdrawal.

2 especially for individuals with histories of alcohol withdrawal.

3 ounted for 68% of the genetic variability in alcohol withdrawal.

4 line) were sensitive to alcohol exposure and alcohol withdrawal.

5 alysis) in 96 sAUD patients hospitalized for alcohol withdrawal.

6 ations, 12 889 (56.3%) used an order set for alcohol withdrawal.

7 ed morbidity, including hospitalizations for alcohol withdrawal.

8 the negative affective state associated with alcohol withdrawal.

9 , probably in the context of intoxication or alcohol withdrawal.

10 ents regimens for patients hospitalized with alcohol withdrawal.

11 e GABA hyposensitivity of VTA neurons during alcohol withdrawal.

12 were absent in MrgprB2-deficient mice during alcohol withdrawal.

13 stress and anxiety symptoms during drug and alcohol withdrawal.

14 plays a role in the aversive consequences of alcohol withdrawal.

15 mood states like anxiety experienced during alcohol withdrawal.

16 ement of the nicotinic cholinergic system in alcohol withdrawal.

17 trial, intranasal oxytocin potently blocked alcohol withdrawal.

18 ce of the Fkbp5 gene enhances sensitivity to alcohol withdrawal.

19 ptor availability during acute and prolonged alcohol withdrawal.

20 e 4 with a large effect on predisposition to alcohol withdrawal.

21 subspecialty consultations, and anticipated alcohol withdrawal.

22 onfidence interval 0.01 to 0.09)), opioid or alcohol withdrawal (0.14 (0.01 to 0.27)), and admissions

23 idence interval 0.08 to 0.69)) and opioid or alcohol withdrawal (0.31 (0.014 to 0.58)), but no change

24 mmonest reason for admission was symptomatic alcohol withdrawal (36%).

25 number of 22-kHz USVs observed during acute alcohol withdrawal and a KOR agonist (U50,488) resulted

26 of the negative affective state produced by alcohol withdrawal and abstinence, which is critical for

27 e medical ICU solely for treatment of severe alcohol withdrawal and b) to determine whether a strateg

28 es negative affective states induced by both alcohol withdrawal and conditioned stimuli as being prod

29 Patients with severe alcohol withdrawal and delirium tremens are frequently r

30 assess patterns of neuronal activity during alcohol withdrawal and following reaccess in a well-char

31 negative affect during acute and protracted alcohol withdrawal and following stress in adulthood.

32 rasonic vocalizations (USVs) associated with alcohol withdrawal and KOR activation in adult male wist

33 nce for beneficial effects of KD on managing alcohol withdrawal and on reducing alcohol drinking.

34 pport the role of ceftriaxone in alleviating alcohol withdrawal and open a novel pharmacologic avenue

35 Negative affective aspects of alcohol withdrawal and pain involve converging brain cir

36 h ongoing trials of PDE4 inhibitors to treat alcohol withdrawal and reduce alcohol consumption.

37 zenil uptake correlated with the severity of alcohol withdrawal and the number of days since the last

38 (KOR) system mediates phenotypes related to alcohol withdrawal and withdrawal-like negative affectiv

39 pendence (alcoholism not in remission and/or alcohol withdrawal) and sepsis, septic shock, and hospit

40 e admitted by a surgical service, have acute alcohol withdrawal, and be managed with pressure-control

41 trations, by drugs used for the treatment of alcohol withdrawal, and by taurine, an ingredient of cer

42 e in the management of seizures secondary to alcohol withdrawal, and in those due to theophylline or

43 , as determined by M30 levels, occurs during alcohol withdrawal, and survival data point toward a nov

44 und to be increased, or not affected, during alcohol withdrawal, and to show no differences from CON

45 f AC differs from DCM and relies directly on alcohol withdrawal, as left ventricular ejection fractio

46 fore tested whether GDNF in the VTA reverses alcohol withdrawal-associated DA deficiency and/or posse

47 06) in heavy drinkers primarily admitted for alcohol withdrawal before and after alcohol detoxificati

48 narrowing are not reversed immediately after alcohol withdrawal but persist during early abstinence.

49 The results indicate that alcohol withdrawal causes headache via MrgprB2 of mast c

50 ble for 26% of the genetic variance in acute alcohol withdrawal convulsion liability to a >35 centimo

51 pression-like behavior in animals undergoing alcohol withdrawal, further advocating the RMTg as a pot

52 central nucleus of the amygdala (CeA) during alcohol withdrawal has been hypothesized to induce high

53 a medical ICU solely for treatment of severe alcohol withdrawal have a high incidence of requiring me

54 ntly increased glutamate levels during acute alcohol withdrawal in corresponding prefrontocortical re

55 Alcohol withdrawal in dependent mice causes changes in b

56 Increased mast cell degranulation by alcohol withdrawal in dura mater was dependent on the pr

57 ons, screening, assessment, and treatment of alcohol withdrawal in the general hospital population.

58 Treatment of alcohol withdrawal in the intensive care unit mirrors th

59 (PACAP), and its cognate receptor, PAC1R, in alcohol withdrawal-induced behaviors.

60 al.(1) identify a peripheral mechanism of an alcohol-withdrawal-induced headache-like condition, whic

61 cific receptor MrgprB2 in the development of alcohol-withdrawal-induced headache.

62 appropriate therapeutic option available for alcohol-withdrawal-induced headaches.

63 or developing novel treatment approaches for alcohol-withdrawal-induced mood and anxiety disorders.

64 Alcohol withdrawal is associated with hypothalamic-pitui

65 m is related to genetic differences in acute alcohol withdrawal liability.

66 indicating that MPDZ variants may influence alcohol withdrawal liability.

67 ribute to adverse affective disorders during alcohol withdrawal, likely through PKC-gamma/betaCaMKII-

68 Adjunctive dexmedetomidine for severe alcohol withdrawal maintains symptom control and reduces

69 the deficiency of RMTg NOP signaling during alcohol withdrawal mediates anxiety- and depression-like

70 ns in alcohol-withdrawal WT mice, but not in alcohol-withdrawal MrgprB2-deficient mice.

71 m tremens, the most serious manifestation of alcohol withdrawal, occurs in approximately 5% of hospit

72 red either following short periods (24 h) of alcohol withdrawal, or 90 m following alcohol consumptio

73 or treating anxiety, epilepsy, muscle spasm, alcohol withdrawal, palliation, insomnia, and sedation a

74 C demethylases in hepatocytes at the time of alcohol withdrawal promoted fibrosis resolution.

75 This cohort study examines whether alcohol withdrawal rates among hospitalized patients wit

76 e anhedonia and depression-like behaviors in alcohol-withdrawal rats.

77 f amygdala) and prevented the development of alcohol withdrawal-related anxiety in rats as measured b

78 t MrgprB2 is a potential target for treating alcohol-withdrawal-related headaches.

79 rity was recorded using the Glasgow Modified Alcohol Withdrawal Score (GMAWS).

80 interval-specific congenic lines, show that alcohol withdrawal severity is genetically correlated wi

81 reases in cell proliferation correlated with alcohol withdrawal severity, proliferation remained incr

82 ere mapped that contain genes that influence alcohol withdrawal severity.

83 the effect of Fkbp5 gene deletion in mice on alcohol withdrawal severity.

84 sed analyses also showed an association with alcohol withdrawal severity.

85 that this effect was more pronounced during alcohol withdrawal, suggesting that AdipoR2 signaling ma

86 lyses indicated a significant interaction of alcohol withdrawal symptom score by treatment by full-do

87 ronic, heavy use increases the likelihood of alcohol withdrawal symptoms and associated secondary out

88 ntin has demonstrated efficacy in mitigating alcohol withdrawal symptoms and preventing relapse drink

89 The findings indicate that alcohol withdrawal symptoms are a significant moderator

90 These data support further evaluation of alcohol withdrawal symptoms as a prognostic indicator of

91 ol dependence (N=100) with varying levels of alcohol withdrawal symptoms assessed at treatment entry.

92 The authors examined whether alcohol withdrawal symptoms moderate the efficacy of pra

93 Individuals with high alcohol withdrawal symptoms on prazosin compared with pl

94 By week 12, participants with high alcohol withdrawal symptoms on prazosin reported 7.07% h

95 lly, to investigate the effect of MT-7716 on alcohol withdrawal symptoms, Wistar rats were withdrawn

96 MT-7716 significantly attenuated somatic alcohol withdrawal symptoms.

97 in was observed in those reporting low or no alcohol withdrawal symptoms.

98 be potential therapeutic agents in treating alcohol withdrawal symptoms.

99 BA(A)) receptor-facilitating agents suppress alcohol withdrawal symptoms.

100 ent of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial

101 ption (r42 = -0.32, P < .05) and more severe alcohol-withdrawal symptoms (r38 = -0.35, P < .05).

102 CIE is validated as a model for human alcohol withdrawal syndrome (AWS) by demonstrating incre

103 al monotherapy is increasingly used to treat alcohol withdrawal syndrome (AWS) in hospitalized patien

104 Alcohol withdrawal syndrome (AWS) is a common inpatient

105 Alcohol withdrawal syndrome (AWS) is a potentially fatal

106 Alcohol withdrawal syndrome (AWS) is an important cause

107 Alcohol withdrawal syndrome (AWS) occurs in 2% of patien

108 Alcohol withdrawal syndrome (AWS) symptoms include hyper

109 Background: Severe alcohol withdrawal syndrome (SAWS) is highly morbid, cos

110 ine occurrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens in pati

111 Measures included occurrence of alcohol withdrawal syndrome and delirium tremens, injury

112 Attempts at abstinence lead to alcohol withdrawal syndrome and hyperalgesia, increasing

113 commonly used to treat complications such as alcohol withdrawal syndrome are often contraindicated by

114 Alcohol withdrawal syndrome assessment and its treatment

115 ital length of stay, ICU length of stay, and alcohol withdrawal syndrome complications differed signi

116 Alcohol withdrawal syndrome developed in 0.88% (n = 246)

117 Trauma patients with alcohol withdrawal syndrome experience a high occurrence

118 factors, and screening tools associated with alcohol withdrawal syndrome in the ICU are reviewed.

119 The role of currently published alcohol withdrawal syndrome pharmacologic strategies (be

120 Alcohol withdrawal syndrome progressed to delirium treme

121 mia, baseline CIWA-Ar score, and established alcohol withdrawal syndrome risk factors.

122 rome complications differed significantly by alcohol withdrawal syndrome severity and were worse with

123 Mortality also significantly differed by alcohol withdrawal syndrome severity but was only greate

124 Before adjustment, alcohol withdrawal syndrome severity was associated with

125 Alcohol withdrawal syndrome severity was defined by CIWA

126 stigate non-y-aminobutyric acid pathways for alcohol withdrawal syndrome treatment; 2) harnessing ret

127 4%, and 0% by minimal, moderate, and severe alcohol withdrawal syndrome).

128 inical outcomes, pharmacologic treatment for alcohol withdrawal syndrome, and Clinical Institute With

129 s repeated alcohol use leading to tolerance, alcohol withdrawal syndrome, and physical and psychologi

130 ns, injury characteristics, risk factors for alcohol withdrawal syndrome, clinical outcomes, pharmaco

131 extremely complex, as manifestations such as alcohol withdrawal syndrome, craving and physical depend

132 , 68 adults with AUD, including a history of alcohol withdrawal syndrome, received 1,200 mg/day of ga

133 In patients with severe alcohol withdrawal syndrome, severe head injury also pre

134 included pain, sedation, status asthmaticus, alcohol withdrawal syndrome, status epilepticus, and acu

135 ting critically ill patients including pain, alcohol withdrawal syndrome, status epilepticus, and acu

136 ere worse with more severe manifestations of alcohol withdrawal syndrome.

137 a genetic effect of FKBP5 on the severity of alcohol withdrawal syndrome.

138 to withdrawal symptoms in ICU patients with alcohol withdrawal syndrome.

139 ize studies addressing the drug treatment of alcohol withdrawal syndromes in inpatient populations, w

140 al pharmacologic strategies for treatment of alcohol withdrawal syndromes in the critically ill.

141 pathophysiology, diagnosis, and treatment of alcohol withdrawal syndromes in the intensive care unit

142 h the diagnosis and treatment strategies for alcohol withdrawal syndromes in the intensive care unit.

143 ns in dopamine transporter (DAT) sites after alcohol withdrawal, the role of DAT in influencing eithe

144 tribute to neuronal hyperexcitability during alcohol withdrawal, these findings suggest an important

145 O) and wild-type (WT) mice were assessed for alcohol withdrawal using handling-induced convulsions (H

146 Acute alcohol withdrawal was accompanied by downregulated GR m

147 trexone-gabapentin group, while a history of alcohol withdrawal was associated with better response i

148 Short-term alcohol withdrawal was associated with the recovery of l

149 et without the need for medically supervised alcohol withdrawal were included.

150 related to unhealthy alcohol consumption and alcohol withdrawal were invited to participate in a work

151 nvolved in a negative emotional state during alcohol withdrawal, which can lead to relapse.

152 tral role for the LHb in hyperalgesia during alcohol withdrawal, which may be due in part to the supp

153 uroadaptations in GABAA receptor levels over alcohol withdrawal will provide critical insights for th

154 aptive changes in HPA axis regulation during alcohol withdrawal with concomitant effects on withdrawa

155 o identify, assess, risk-stratify, and treat alcohol withdrawal with evidence based interventions.

156 We report that alcohol withdrawal with or without concurrent tobacco sm

157 he observed increase in HDAC activity during alcohol withdrawal with the HDAC inhibitor, trichostatin

158 , which confirms capture of a gene affecting alcohol withdrawal within the <1 cM interval.

159 zation of trigeminal ganglia (TG) neurons in alcohol-withdrawal WT mice, but not in alcohol-withdrawa